Further receiver operating curve (ROC) analysis showed that GPS1 had a certain degree of accuracy in predicting the occurrence of breast cancer; prognostic analysis revealed that those with high expression of GPS1 had a worse prognosis in Luminal B, low to intermediate-grade breast cancers; and there was a significant negative correlation between the expression of GPS1 and the prognosis of patients without lymph node metastasis. Here, GPS1 is linked to breast cancer.